LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENTLubiprostone Exclusive Manufacturing and Supply Agreement • March 16th, 2009 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT (“Agreement”) is made this 23th day of February, 2009 (the “Effective Date”), by and among Sucampo Pharma, Ltd., a corporation organized and existing under the laws of Japan and a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware, U.S.A., and having its principal office at Sakurabashi Toyo Building, Fourth Floor, 2-2-16 Sonezakishinchi, Kita-ku, Osaka 530-0002 (“SPL”), R-Tech Ueno, Ltd., a corporation organized and existing under the laws of Japan and having its registered office at 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011 (“RTU”) (each referred to herein as a “Party” and collectively as the “Parties”).
LICENSE, COMMERCIALIZATION AND SUPPLY AGREEMENT FOR LUBIPROSTONE FOR JAPAN by and between ABBOTT JAPAN CO. LTD and SUCAMPO PHARMA, LTD. Dated as of February 19, 2009, and Supply Agreement • March 16th, 2009 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This LICENSE, COMMERCIALIZATION, AND SUPPLY AGREEMENT FOR LUBIPROSTONE FOR JAPAN (“Agreement”) is entered into as of February 19, 2009, by and between Sucampo Pharma, Ltd., a corporation organized under the laws of Japan with principal offices at 2-2-2 Uchisaiwai-cho, Chiyoda-ku, Tokyo, 100-0011, Japan (“Sucampo”) and Abbott Japan Co. Ltd., a corporation organized under the laws of Japan with principal offices at 3-5-27 Mita, Minato-ku, Tokyo 108-6303, Japan (“Abbott”). Each of Abbott and Sucampo is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
